Notice Number: NOT-AI-16-030
Release Date: February 1, 2016. This RFP will be available electronically on/about February 5, 2016.
National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), conducts and supports research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. The mission of the Division of AIDS (DAIDS), NIAID, NIH, is to bring an end to the HIV/AIDS epidemic by increasing basic knowledge of the pathogenesis and transmission of HIV, supporting the advancement of therapies for HIV infection and its complications, and supporting the development of HIV/AIDS vaccines and other prevention measures. NIAID/DAIDS, henceforth referred to as DAIDS, supports extramural Clinical Trials Networks, investigator-initiated clinical trials, and partners with other Government and private organizations to accomplish the Division’s scientific objectives. Through grants and contracts, DAIDS sponsors Phase I, II, III and IV clinical trials to evaluate the safety and efficacy of therapeutics, vaccines, and other preventive modalities.
DAIDS acts as study sponsor for clinical trials that meet the requirements to be conducted under Health Authority (HA) oversight (U.S. Food and Drug Administration [FDA] and others as appropriate), of Investigational New Drug (IND) studies, as well as those studies that do not meet these requirements (non-IND). As of May 2015, there are 61 active INDs containing 117 protocols (86 active), and 1342 clinical research sites (718 domestic, 624 international) with trials being conducted in 64 (22 active) different countries. As the IND sponsor for a large number of DAIDS-supported clinical trials, there is an established requirement for DAIDS to provide regulatory support for these clinical trials to ensure compliance with applicable regulations, including Title 21 Code of Federal Regulations (CFR) Parts 11, 50, 54, 56, 312, and 314 and Title 45 CFR Part 46. Clinical trials must also be conducted in accordance with the International Conference on Harmonisation (ICH) Guidelines: E2A Clinical Safety Data Management and E6 Good Clinical Practices (GCP), and country-specific regulatory requirements.
The purpose of the contract is to provide regulatory expertise and support to operate and manage the Division of AIDS (DAIDS) Regulatory Support Center (RSC) to provide a wide range of clinical research activities and programs for DAIDS. The DAIDS RSC provides comprehensive regulatory support to: 1) perform DAIDS-funded and DAIDS-sponsored domestic and international clinical trial research trials; 2) provide training in key functions of clinical trial research to DAIDS staff, investigators and collaborators; and 3) maintain all contract-associated data and records in the DAIDS Enterprise System (DAIDS-ES) and NIAID-Clinical Research Management System (N-CRMS), including the electronic submission of required regulatory information.
The current NIAID/Division of AIDS: Regulatory Support contract was awarded to Technical Resources International, (TRI) Inc., Bethesda, Maryland on April 15, 2010, for a total period of seven years.
Offerors should have the qualifications, experience and capability to perform this requirement. Specifically, the Contractor shall:
It is anticipated that one cost-plus-award fee, level-of-effort (term) type contract will be awarded. The Contracting Officer has determined that a performance based contract is suitable for this acquisition. An Award Fee Plan will be included in the solicitation. The period of performance will be for one year (Base Period) plus six one-year options (terms) that may be exercised by the Government unilaterally, for a total possible performance period of seven years, beginning on or about February 15, 2017. The requirement will be for the delivery of 48.45 full time equivalents (FTEs) per year, inclusive of subcontractors and consultants, for the Base Period (Year 1) and each option period (Years 2 through 7).
In addition, the Government may unilaterally exercise options for an increased level of effort that may result from unanticipated increases in demand for the activities supported by the base requirements of this contract. Options for increased services may include:
Increased Level of Effort (1.0 FTE): The Government may exercise options for incremental increases in the level of effort. Such an increase would require an increase in the Contractor's activities to be activated, at the discretion of the Government, as an option. For each option quantity exercised, the Contractor shall provide an additional 1.0 FTE, inclusive of subcontractor and consultant effort. Up to two Options per year may be exercised during years 1 through 7 of contract performance.
Increased Level of Effort (2.0 FTEs): The Government may exercise options for incremental increases in the level of effort. Such an increase would require an increase in the Contractor's activities to be activated, at the discretion of the Government, as an option. For each option quantity exercised, the Contractor shall provide an additional 2.0 FTEs, inclusive of subcontractor and consultant effort. Up to two Options per year may be exercised during years 1 through 7 of contract performance.
Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about February 5, 2016, and may be accessed through FedBizOpps http://www.fedbizopps.gov/. This Notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
For this solicitation, the NIAID requires proposals to be submitted via two methods: (1)
Disc (CD or DVD) and (2) Online via the NIAID electronic Contract Proposal Submission (eCPS) website. The content of the disc and online proposals must be identical. Submission of proposals by facsimile or e-mail is not acceptable.
For directions on using eCPS, go to the website https://ecps.niaid.nih.gov and then click on "How to Submit."
Please direct all inquiries to:
National Institute of Allergy & Infectious Diseases (NIAID)
John R. Manouelian
National Institute of Allergy & Infectious Diseases (NIAID)